TABLE 3.
Summary of recent meta-analyses that focused on clinical studies of continuous infusion and prolonged infusion of beta-lactamsa
| Reference | Study design(s)/no. of studies | Beta-lactam class(es) | No. of patients analyzed for each outcome (mortality/clinical cure) | Mortality (RR/95% CI) | Clinical cure (RR/95% CI) |
|---|---|---|---|---|---|
| Tamma et al., 2011(93) | RCT/14 | Pcn, Ceph, Car | 982/1,380 | 0.92/0.61–1.37 | 1.00/0.94–1.06 |
| Falagas et al., 2013 (4) | RCT/3; retrospective/8; prospective/3 | Pcn, Car | 1,116/557 | 0.59/0.41–0.83 | 1.13/0.99–1.28 |
| Korbila et al., 2013 (97) | RCT/10; retrospective/1 | Ceph | 914/496 | 0.96/0.8–1.15 | 1.14/0.94–1.37 |
| Teo et al., 2014 (99) | RCT/18; prospective/3; retrospective/8 | Pcn, Ceph, Car | 1,620/1,546 | 0.66/0.53–0.83 | 1.12/1.03–1.21 |
| Yang et al., 2015 (100) | RCT/5; prospective/2; retrospective/7 | Pcn | 1,591/718 | 0.67/0.5–0.89 | 1.88/1.29–2.73 |
| Roberts et al. 2016 (102) | RCT/3 | Pcn, Car | 632/632 | 0.74/0.56–1 | 1.2/1.03–1.4 |
a
Abbreviations: RCT, randomized controlled trial; Pcn, penicillin; Ceph, cephalosporin; Car, carbapenem; RR, relative risk; CI, confidence interval.